As omicron potentially threatens monoclonal therapies efficacy, FDA health panel endorses first at-home COVID-19 treatment pill

Published November 30, 2021 42 Views

Rumble As omicron sounds the alarm as a new variant of concern, Regeneron announced it is now re-evaluating its monoclonal antibody treatment.

BREAKING: Rumble to Combine with NASDAQ listed CFVI